McKesson Corporation (NYSE:MCK) Investor Securities Class Action Lawsuit 10/26/2018

If you purchased a significant amount of shares of McKesson Corporation (NYSE:MCK) between October 24, 2013 and January 25, 2017, and / or if you purchased any NYSE:MCK shares prior to October 2013 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: December 25, 2018. NYSE:MCK investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
McKesson Corp.
Case Name: 
McKesson Corp. Shareholder Class Action Lawsuit 10/26/2018
Case Status: 
Lawsuit Filed
Affected Securities
NYSE: MCK
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
10/26/2018
Class Period Begin: 
10/24/2013
Class Period End: 
01/25/2017
Court of Filing: 
U.S. District Court for the Northern District of California
Deadline To File for Lead: 
12/25/2018
Summary: 

An investor in shares of McKesson Corporation (NYSE:MCK) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by McKesson Corporation in connection with certain allegedly false and misleading statements made between October 24, 2013 and January 25, 2017.

On January 17, 2017, it was announced that McKesson agreed to pay a record $150 million civil penalty for alleged violations of the Controlled Substance Act.

According to the complaint the plaintiff alleges on behalf of purchasers of McKesson Corporation (NYSE:MCK) common shares between October 24, 2013 and January 25, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 24, 2013 and January 25, 2017, the Defendants made false and/or misleading statements and/or failed to disclose that McKesson and several of its industry peers colluded to fix the price of certain generic drugs, that the collusive conduct constituted a violation of federal antitrust laws, that consequently, McKesson’s revenues during the Class Period were, in part, the result of illegal conduct and were therefore unsustainable, that McKesson lacked effective internal controls over financial reporting, and that as a result, McKesson’s public statements were materially false and misleading at all relevant times.